S
Samuel Oommen
Researcher at John Muir Health
Publications - 9
Citations - 1339
Samuel Oommen is an academic researcher from John Muir Health. The author has contributed to research in topics: Neoadjuvant therapy & Colorectal cancer. The author has an hindex of 6, co-authored 8 publications receiving 960 citations.
Papers
More filters
Journal ArticleDOI
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial
Julio Garcia-Aguilar,Oliver S. Chow,David D. Smith,Jorge E. Marcet,Peter A. Cataldo,Madhulika G. Varma,Anjali S. Kumar,Samuel Oommen,Theodore Coutsoftides,Steven R. Hunt,Michael J. Stamos,Charles A. Ternent,Daniel O. Herzig,Alessandro Fichera,Blase N. Polite,David W. Dietz,Sujata Patil,Karin Avila +17 more
TL;DR: Delivery of mFOLFOX6 after chemoradiation and before total mesorectal excision has the potential to increase the proportion of patients eligible for less invasive treatment strategies; this strategy is being tested in phase 3 clinical trials.
Journal ArticleDOI
Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial
Julio Garcia-Aguilar,Lindsay A. Renfro,Oliver S. Chow,Qian Shi,Xiomara W. Carrero,Patricio B. Lynn,Charles R. Thomas,Emily Chan,Peter A. Cataldo,Jorge E. Marcet,David S. Medich,Craig S. Johnson,Samuel Oommen,Bruce G. Wolff,Alessio Pigazzi,Shane M McNevin,Roger K Pons,Ronald Bleday +17 more
TL;DR: The data suggest that nCRT followed by LE may be considered as an organ-preserving alternative in carefully selected patients with clinically-staged T2N0 tumours who refuse, or are not candidates for, transabdominal resection.
Journal ArticleDOI
A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial
Julio Garcia-Aguilar,Qian Shi,Charles R. Thomas,Emily Chan,Peter A. Cataldo,Jorge E. Marcet,David S. Medich,Alessio Pigazzi,Samuel Oommen,Mitchell C. Posner +9 more
TL;DR: CRT before LE for T2N0 tumors results in a high pathologic complete response rate and negative resection margins, however, complications during CRT and after LE are high.
Journal ArticleDOI
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy
Julio Garcia-Aguilar,Sujata Patil,Marc J. Gollub,Jin-Ki Kim,Jonathan B. Yuval,Hannah Thompson,Floris S Verheij,Dana Omer,Meghan Lee,Richard F. Dunne,Jorge E. Marcet,Peter A. Cataldo,Blase N. Polite,Daniel O. Herzig,David Liska,Samuel Oommen,Charles M. Friel,Charles A. Ternent,Andrew L. Coveler,Steven C. Hunt,Anita Gregory,Madhulika G. Varma,Brian Bello,Joseph C. Carmichael,John C. Krauss,Ana Gleisner,Philip B. Paty,Martin R. Weiser,Garrett M. Nash,Emmanouil P. Pappou,J. Guillem,Larissa K. Temple,Iris H Wei,Maria Widmar,Sabrina Lin,Neil H. Segal,Andrea Cercek,Rona Yaeger,J. R. Smith,Karyn A. Goodman,Abraham J. Wu,Leonard B. Saltz +41 more
TL;DR: Organ preservation is achievable in half of the patients with rectal cancer treated with total neoadjuvant therapy, without an apparent detriment in survival, compared with historical controls treated with chemoradiotherapy, TME, and postoperative chemotherapy.
Journal ArticleDOI
Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: Final results of a multicenter phase II trial
Michael R. Marco,Lihong Zhou,Sujata Patil,Jorge E. Marcet,Madhulika G. Varma,Samuel Oommen,Peter A. Cataldo,Steven R. Hunt,Anjali S. Kumar,Daniel O. Herzig,Alessandro Fichera,Blase N. Polite,Neil Hyman,Charles A. Ternent,Michael J. Stamos,Alessio Pigazzi,David W. Dietz,Yuliya Yakunina,Raphael Pelossof,Julio Garcia-Aguilar +19 more
TL;DR: Adding modified FOLFOX6 after chemoradiotherapy and before total mesorectal excision increases compliance with systemic chemotherapy and disease-free survival in patients with locally advanced rectal cancer.